Results 31 to 40 of about 83,328 (323)

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

New England Journal of Medicine, 2018
BACKGROUND Nivolumab plus ipilimumab showed promising efficacy for the treatment of non–small‐cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of benefit.
M. Hellmann, T. Ciuleanu, A. Płużański, J. Lee, G. Otterson, C. Audigier-Valette, E. Minenza, H. Linardou, S. Burgers, P. Salman, H. Borghaei, S. Ramalingam, J. Brahmer, M. Reck, K. O'Byrne, W. Geese, G. Green, Han-Cheng Chang, J. Szustakowski, P. Bhagavatheeswaran, D. Healey, Yali Fu, F. Nathan, L. Paz-Ares   +23 more
semanticscholar   +1 more source

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

New England Journal of Medicine, 2019
BACKGROUND In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed ...
M. Hellmann, L. Paz-Ares, R. Bernabé Caro, B. Żurawski, Sang-We Kim, E. Carcereny Costa, Keunchil Park, A. Alexandru, L. Lupinacci, Emmanuel de la Mora Jimenez, H. Sakai, I. Albert, A. Vergnenègre, S. Peters, K. Syrigos, F. Barlesi, M. Reck, H. Borghaei, J. Brahmer, K. O'Byrne, W. Geese, P. Bhagavatheeswaran, S. Rabindran, Ravi S. Kasinathan, F. Nathan, S. Ramalingam   +25 more
semanticscholar   +1 more source

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Journal of Clinical Oncology, 2022
PURPOSE Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4–blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma, leading to broad regulatory ...
M. Atkins, Sandra J. Lee, B. Chmielowski, A. Tarhini, G. Cohen, T. Truong, H. Moon, D. Davar, M. O'Rourke, J. Stephenson, B. Curti, W. Urba, J. Brell, P. Funchain, K. Kendra, A. Ikeguchi, A. Jaslowski, C. Bane, Mark Taylor, Madhuri Bajaj, R. Conry, Robert J Ellis, T. Logan, N. Laudi, J. Sosman, David G. Crockett, A. Pecora, I. Okazaki, S. Reganti, S. Chandra, S. Guild, Helen X. Chen, H. Streicher, J. Wolchok, A. Ribas, J. Kirkwood   +35 more
semanticscholar   +1 more source

Acute visual loss after ipilimumab treatment for metastatic melanoma

Journal for ImmunoTherapy of Cancer, 2016
Background Ipilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma. While ipilimumab provides an overall survival benefit to patients, it can be associated with immune related adverse events (IrAEs).Case ...
Melissa A. Wilson, Kelly Guld, Steven Galetta, Ryan D. Walsh, Julia Kharlip, Madhura Tamhankar, Suzanne McGettigan, Lynn M. Schuchter, Leslie A. Fecher   +8 more
doaj   +1 more source

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. [PDF]

, 2020
Although immunotherapies have achieved remarkable salutary effects among subgroups of advanced cancers, most patients do not respond. We comprehensively evaluated biomarkers associated with the "cancer-immunity cycle" in the pan-cancer setting in order ...
Dressman, Devin, Eskander, Ramez, Glenn, Sean T, Goodman, Aaron, Ikeda, Sadakatsu, Kato, Shumei, Kumaki, Yuichi, Kurzrock, Razelle, Lee, Suzanna, Lenzo, Felicia L, Morrison, Carl, Nikanjam, Mina, Okamura, Ryosuke, Papanicolau-Sengos, Antonios   +13 more
core   +1 more source

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

Journal of Clinical Oncology, 2022
PURPOSE We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic non–small-cell lung cancer, regardless of tumor programmed death ligand 1 (PD ...
J. Brahmer, Jong-Seok Lee, T. Ciuleanu, R. Bernabé Caro, M. Nishio, L. Urban, C. Audigier-Valette, L. Lupinacci, R. Sangha, A. Płużański, J. Burgers, M. Mahave, Samreen Ahmed, A. Schoenfeld, L. Paz-Ares, M. Reck, H. Borghaei, K. O'Byrne, Ravi G. Gupta, J. Bushong, Li Li, S. Blum, Laura J. Eccles, S. Ramalingam   +23 more
semanticscholar   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Immune checkpoint inhibitors in renal cell carcinoma [PDF]

, 2017
The immune system has long been known to play a critical role in the body's defence against cancer, and there have been multiple attempts to harness it for therapeutic gain.
Jones, Robert J., Ross, Kirsty
core   +1 more source

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. [PDF]

, 2016
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being ...
Bander, Neil H, Beer, Tomasz M, Drake, Charles G, Fong, Lawrence, Gulley, James L, Harrelson, Stacey, Kantoff, Philip W, Madan, Ravi A, McNeel, Douglas G, Oh, William K, Peace, David J, Petrylak, Daniel P, Porterfield, Hank, Sartor, Oliver, Shore, Neal D, Slovin, Susan F, Stein, Mark N, Vieweg, Johannes   +17 more
core   +1 more source

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

Journal of Clinical Oncology, 2022
PURPOSE In patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard of care.
T. André, D. Tougeron, G. Piessen, C. de la Fouchardière, C. Louvet, A. Adenis, M. Jary, C. Tournigand, T. Aparicio, J. Desramé, A. Lièvre, Marie-Line Garcia-Larnicol, T. Pudlarz, R. Cohen, Salomé Memmi, D. Vernerey, J. Henriques, J. Lefèvre, M. Svrcek   +18 more
semanticscholar   +1 more source